ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Humoral Vaccine Responses and One-year Follow-up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-label, Phase IV Studies MINORE and SOPRANINO

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study